XML 42 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Oct. 02, 2016
Jun. 30, 2016
May 31, 2016
Dec. 31, 2015
Jan. 31, 2015
Sep. 30, 2014
Aug. 31, 2012
Dec. 31, 2016
Dec. 31, 2015
Operating lease periodic payment   $ 709     $ 730        
Frequency of periodic payment   Monthly     Monthly        
Operating lease rental expense               $ 4,960 $ 12,053
Operating lease expiration date         Nov. 30, 2015        
SkyPharm [Member]                  
Operating lease periodic payment           $ 4,802      
Operating lease rental expense               89,323 60,614
Term of operating lease           6 years      
SkyPharm [Member] | Additional space [Member]                  
Operating lease periodic payment     $ 2,021            
SkyPharm [Member] | First Floor [Member]                  
Operating lease periodic payment       $ 886          
Amplerissimo [Member]                  
Operating lease periodic payment             $ 122    
Frequency of periodic payment             Monthly    
Operating lease rental expense               $ 1,462 $ 1,462
Operating lease expiration date             Jul. 31, 2013    
Operating lease renewal date             Jul. 31, 2015    
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member]                  
Operating lease periodic payment $ 1,500                
Common stock shares reserved 2,000,000                
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase III testing [Member]                  
Common stock shares reserved 500,000                
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase II testing [Member]                  
Common stock shares reserved 500,000                
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | conclusion of Phase I testing [Member]                  
Common stock shares reserved 500,000                
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Preclinical Trials [Member]                  
Common stock shares reserved 500,000